Abstract: The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.
Type:
Application
Filed:
December 6, 2022
Publication date:
June 22, 2023
Applicant:
Beijing Normal University Hong Kong Baptist University United International College
Abstract: The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
December 13, 2022
Assignee:
Beijing Normal University Hong Kong Baptist University United International College
Abstract: The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.
Type:
Application
Filed:
November 3, 2016
Publication date:
March 28, 2019
Applicant:
Beijing Normal University Hong Kong Baptist University United International College